HBPCF (Helix BioPharma) EBITDA Margin %: 0.00% (As of Apr. 2026)


HBPCF Helix BioPharma Corp HBPCF
28 GF Score
Price $1.71
View Full Analysis

What is Helix BioPharma EBITDA Margin %?

Helix BioPharma HBPCF 28 EBITDA Margin % is 0.00% as of Apr. 2026. GuruFocus rates HBPCF with a GF Score™ of 28/100. Among 945 Biotechnology companies, Helix BioPharma ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Helix BioPharma's EBITDA for the three months ended in Apr. 2026 was $-0.48 Mil. Helix BioPharma's Revenue for the three months ended in Apr. 2026 was $0.00 Mil. Therefore, Helix BioPharma's EBITDA margin for the quarter that ended in Apr. 2026 was 0.00%.

Helix BioPharma  (OTCPK:HBPCF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Helix BioPharma EBITDA Margin % Related Terms

Helix BioPharma EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Helix BioPharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helix BioPharma EBITDA Margin % Chart

Helix BioPharma Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Helix BioPharma Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

HBPCF vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Helix BioPharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Helix BioPharma EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix BioPharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Helix BioPharma's EBITDA Margin % falls into.


HBPCF
28GF Score
Helix BioPharma Corp HBPCF
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helix BioPharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Helix BioPharma's EBITDA Margin % for the fiscal year that ended in Jul. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Jul. 2025 )/Revenue (A: Jul. 2025 )
=-3.787/0
= %

Helix BioPharma's EBITDA Margin % for the quarter that ended in Apr. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Apr. 2026 )/Revenue (Q: Apr. 2026 )
=-0.483/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Helix BioPharma (HBPCF) has a EBITDA Margin % of 0.00% as of Apr. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Helix BioPharma and its competitors. According to the industry distribution chart, Helix BioPharma ranks #999999 out of 945 companies in the Biotechnology industry.
Is Helix BioPharma's EBITDA Margin % too high?
Helix BioPharma's current EBITDA Margin % is 0.00%. Based on the distribution chart, Helix BioPharma ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Helix BioPharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helix BioPharma ranks #999999 out of 945 companies for EBITDA Margin %. This places Helix BioPharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Helix BioPharma and its competitors. Helix BioPharma's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Helix BioPharma's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current EBITDA Margin % is 0.00% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helix BioPharma Business Description

Other Exchanges HBP0:GermanyHBP:Canada
Address 40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
28GF Score

Get the complete analysis for HBPCF

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.71
Price